Karkantzos Theodoros Christos 4

What Happened
Theodoros Christos Karkantzos, a director of Cosmos Health Inc. (COSM), was awarded 20,000 shares of common stock on May 19, 2026 under the company's 2024 & 2025 Omnibus Incentive Plan (value reported at $0.28/share, $5,660). On the same date he also converted 35,000 derivative securities (reported as a "conversion" with $0.00 cash proceeds). The award/vesting and conversion were reported as transactions exempt under Rule 16b-3.

Key Details

• Transaction date: May 19, 2026 (filed with SEC on June 11, 2026)
• Award: 20,000 shares at $0.28 per share — reported value $5,660 (footnote F1)
• Conversion: 35,000 derivative securities converted/settled, $0.00 cash proceeds (footnote F2 notes RSUs granted and vested on the grant date)
• Footnotes: Grants made under the Issuer's 2024 & 2025 Omnibus Incentive Plan; RSUs vested on grant and transactions are Rule 16b-3 exempt
• Shares owned after the transactions: not specified in the provided filing
• Filing timeliness: Filed 23 days after the transaction date (appears late relative to the 2-business-day Form 4 rule)

Context
The 20,000-share entry is an award/vesting of restricted stock units (RSUs), a common form of director compensation and not the same as an open-market purchase. The 35,000-item "conversion" indicates derivative instruments were settled or converted into/from equity with no cash exchanged; the filing shows no sale proceeds. Such awards and conversions are routine corporate compensation events; they are factual disclosures and do not, by themselves, indicate the director's market view.